CELU

About CELU

Celularity Inc. is a clinical-stage biotechnology company engaged in developing off-the-shelf placental-derived allogenic cell therapy product candidates. It operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), unmodified and genetically modified natural killer (NK) cells, mesenchymal-like adherent stromal cells (ASCs), and targeting therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CyCART-19 is a placental-derived CAR-T cell therapy and targeting the CD19 receptor; CYNK-001 is for the treatment of acute myeloid leukemia (AML); CYNK-101 is genetically modified version of a placental-derived NK-cell; APPL-001 developed for the treatment of Crohn’s disease, a degenerative disease, and PDA-002 developed for the treatment of Facioscapulohumeral muscular dystrophy (FSHD).

Buy US stocks in Australia with $0 brokerage and trade CELU today!